Stockreport

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

Alpha Cognition Inc.  (ACOG) 
PDF ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade32 person sales team hired to cover the $2 billion Long-Term-Care marketAll la [Read more]